Pressmeddelande -
Alzinova's drug substance for the Alzheimer ALZ-101 vaccine is now produced for the upcoming clinical Phase 1b study
..............................................................
GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag. Nedan pressmeddelande från Alzinova följer på engelska:
..............................................................
Alzinova AB has secured materials for the clinical Phase 1b study through the manufacturing of the drug substance for the oligomer-specific vaccine ALZ-101. The high-purity material meets the quality requirements of the clinical trial. The clinical trial with ALZ-101 on Alzheimer's disease patients is expected to start during the second quarter of 2021.
CEO Kristina Torfgård comments:
- “We are very pleased that the drug substance for the upcoming clinical Phase 1b study with ALZ-101 is now manufactured. For us, this is an important milestone, showing that the drug substance for the ALZ-101 vaccine can be manufactured to a good quality for clinical trials. This important information allows us to look forward to the further preparations for initiating the first clinical study with this therapeutic vaccine in Alzheimer's disease patients during the second quarter of 2021,” says Kristina Torfgård, CEO.
For more information, please contact:
Kristina Torfgård, CEO
Telephone: +46 70 846 79 75
E-mail: kristina.torfgard@alzinova.com
The information was submitted for publication, through the agency of the contact person set out above, at 08.01 CET on January 8, 2020.
About Alzinova AB
Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer’s disease by targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North is Corpura Fondkommission AB, info@corpura.se, +46 (0)768-532 822. For more information about Alzinova, please visit: www.alzinova.com
Ämnen
Kategorier
Regioner
About GU Ventures AB
GU Ventures builds businesses out of groundbreaking ideas that help shape a better tomorrow and is top-ranked by UBI Global Index as one of the world's 20 leading university-run incubators. We finance and develop new innovative business ideas with connections to the University of Gothenburg, which is one of northern Europe's largest universities. Our mission is commercialize the innovations, which leads to the utilization of research and skills, renewal of the business community, job creation and sustainable growth. Our passionate team of company builders, financial experts, IP and legal talent are dedicated supporters of our companies and ensure their successes. Since our starting point in 1995, GU Ventures has developed over 200 new business ideas of which 130 are in business today and of which 14 are listed. Our portfolio consists of 70 holdings and some projects. In the latest survey, 87% of companies match the global sustainability goals set by the UN. GU Ventures is wholly owned by the Swedish state and managed by the University of Gothenburg. Feel free to read more at: www.guventures.com.
